Patents Assigned to Stowers Institute for Medical Research
-
Patent number: 8546545Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.Type: GrantFiled: March 22, 2012Date of Patent: October 1, 2013Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Publication number: 20130252338Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.Type: ApplicationFiled: May 20, 2013Publication date: September 26, 2013Applicant: Stowers Institute for Medical ResearchInventors: John M. PERRY, Linheng LI, Justin C. GRINDLEY
-
Patent number: 8519105Abstract: The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.Type: GrantFiled: February 18, 2011Date of Patent: August 27, 2013Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Publication number: 20130209474Abstract: The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways.Type: ApplicationFiled: April 16, 2013Publication date: August 15, 2013Applicant: Stowers Institute for Medical ResearchInventor: Stowers Institute for Medical Research
-
Patent number: 8476071Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.Type: GrantFiled: August 9, 2012Date of Patent: July 2, 2013Assignee: Stowers Institute for Medical ResearchInventors: John M. Perry, Linheng Li, Justin C. Grindley
-
Patent number: 8263403Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.Type: GrantFiled: April 23, 2008Date of Patent: September 11, 2012Assignee: Stowers Institute for Medical ResearchInventors: John M. Perry, Linheng Li, Justin C. Grindley
-
Patent number: 8173125Abstract: The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways.Type: GrantFiled: February 18, 2011Date of Patent: May 8, 2012Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 8168761Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.Type: GrantFiled: February 18, 2011Date of Patent: May 1, 2012Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 8106166Abstract: The present invention relates to a purified molecules, including antibodies, that bind specifically to murine ?-catenin phosphorylated at amino acid position Serine552 and to orthologs thereof, such as mammalian orthologs, including human orthologs. Methods of making and using such purified molecules are also provided. Kits containing such purified molecules are further provided.Type: GrantFiled: March 17, 2008Date of Patent: January 31, 2012Assignee: Stowers Institute for Medical ResearchInventors: Xi He, Tong Yin, Qiang Tian, Weiguo Tao, Leroy Hood, Linheng Li
-
Patent number: 8007790Abstract: The present invention is directed to methods of treating or ameliorating an effect of a polycystic disease. More particularly, the methods include administering to a patient in need thereof an amount of a modulator of a tumor necrosis factor (TNF) pathway, which is sufficient to treat or ameliorate an effect of a polycystic disease. Methods of treating or ameliorating an effect of a polycystic kidney disease (PKD) are also provided. Methods are also provided for identifying a candidate compound that may be effective to treat or ameliorate an effect of a polycystic disease or to increase polycystin-2 (PC2) function or decrease Rab11-Family of Interacting Protein2 (FIP2) function. Further provided are methods for identifying a patient having, or who is at risk for developing, a polycystic disease or who would benefit from treatment with a TNF-alpha inhibitor.Type: GrantFiled: October 2, 2007Date of Patent: August 30, 2011Assignee: Stowers Institute for Medical ResearchInventors: Rong Li, Xiaogang Li
-
Patent number: 7968301Abstract: The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways.Type: GrantFiled: November 16, 2007Date of Patent: June 28, 2011Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 7915037Abstract: The invention provides a Dre/rox recombinase system. In particular, the invention provides Dre polypeptides that can catalyze site-specific recombination at rox sites but not at lox sites. The Dre/rox system can be utilized in a number of genetic manipulations either alone or in combination with other recombinase systems.Type: GrantFiled: July 7, 2008Date of Patent: March 29, 2011Assignee: Stowers Institute for Medical ResearchInventors: Brian L. Sauer, Jeffrey McDermott
-
Patent number: 7914786Abstract: The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.Type: GrantFiled: July 6, 2009Date of Patent: March 29, 2011Assignee: Stowers Institute For Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 7893218Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.Type: GrantFiled: August 23, 2006Date of Patent: February 22, 2011Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 7585501Abstract: The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.Type: GrantFiled: December 20, 2006Date of Patent: September 8, 2009Assignee: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 7488582Abstract: The present invention relates to methods of diagnosing spondylocostal dysostosis (SCD) disorders, such as Jarcho-Levin syndrome, in humans for use in genetic counseling and linkage analyses. Methods and compositions for measuring the presence or absence of a specific mutation to Mesp2 associated with Jarcho-Levin syndrome, alone or in combination with other mutations associated with spondylocostal dysostosis, are provided.Type: GrantFiled: November 2, 2006Date of Patent: February 10, 2009Assignee: Stowers Institute For Medical ResearchInventors: Olivier Pourquie, Karen Staehling-Hampton, Kym Delventhal
-
Patent number: 7422889Abstract: The invention provides a Dre/rox recombinase system. In particular, the invention provides Dre polypeptides that can catalyze site-specific recombination at rox sites but not at lox sites. The Dre/rox system can be utilized in a number of genetic manipulations either alone or in combination with other recombinase systems.Type: GrantFiled: December 29, 2004Date of Patent: September 9, 2008Assignee: Stowers Institute for Medical ResearchInventors: Brian L. Sauer, Jeffrey McDermott
-
Publication number: 20070292444Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.Type: ApplicationFiled: August 23, 2006Publication date: December 20, 2007Applicant: Stowers Institute for Medical ResearchInventors: Robb Krumlauf, Debra Ellies
-
Patent number: 7285699Abstract: A gene targeting method for use in a host organism whereby the host organism is transfected with an ends-out donor construct. Further transfecting the host organism with two transgenes expressing endonuclease and recombinase enzymes. The endonuclease and recombinase enzymes are used so that homologous recombination occurs between the DNA segment of the donor construct and a selected gene of the host organism, thus forming a host with containing the recombinogenic donor. The progeny of the host organism, which include the recombinogenic donor are then selected.Type: GrantFiled: May 9, 2003Date of Patent: October 23, 2007Assignee: Stowers Institute for Medical ResearchInventors: Kent G. Golic, Wei J. Gong
-
Proteins capable of regulating NF-.kappa.B, JNK and apoptosis pathways and methods of using the same
Patent number: 6160095Abstract: Testing methods are provided for determining whether given candidate compounds are effective for regulating NF-.kappa.B, JNK and apoptosis cell activities. The methods involve forming a mixture including a compound such as a proteinaceous specie containing two death effector domains (DEDs) or structural or functional homologs and analogs thereof, the candidate compound and a binding target capable of specifically binding to at least one of the DEDs. This mixture is incubated under conditions such that, but for the presence of the candidate compound, the cell activity takes place to a determinable extent. After incubation, the activity is determined and is compared with the determinable extent thereof in the absence of the candidate compound. The assays may be carried out intracellularly or in a cell-free assay. Methods for altering NF-.kappa.Type: GrantFiled: August 24, 1999Date of Patent: December 12, 2000Assignees: University of Washington, Stowers Institute for Medical ResearchInventors: Preet M. Chaudhary, Leroy Hood